A clinical trial involving linaclotide was updated on July 29, 2026, according to ClinicalTrials.gov. The study, titled "A Study of Virtual Reality and Linaclotide for IBS-C," is registered under identifier NCT05796388. Its current status is listed as recruiting.
The trial does not have a designated phase, as it is marked "NA" in the registry. It examines linaclotide in combination with virtual reality in the context of IBS-C, according to the listing title.
No results have been posted for this trial as of the date reported. The recruiting status indicates the study is currently enrolling participants rather than reporting outcomes. No efficacy or safety conclusions can be drawn from a recruiting status alone.
Linaclotide is an approved compound, and this trial update reflects ongoing research activity rather than a change in its approved use. Readers interested in the study can refer to the ClinicalTrials.gov listing for enrollment criteria and additional trial details as they become available.
For general background on linaclotide, readers can consult the compound overview for further context.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT05796388"]